New York, June 17, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Research Antibodies Industry" - https://www.reportlinker.com/p06032766/?utm_source=GNW
3% over the period 2020-2027. Reagent, one of the segments analyzed in the report, is projected to record 4.8% CAGR and reach US$9.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antibodies segment is readjusted to a revised 6.3% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 4.9% CAGR
- The Research Antibodies market in the U.S. is estimated at US$2.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.
- Select Competitors (Total 42 Featured) -
- Abcam plc
- Active Motif, Inc.
- Affinity Biologicals, Inc.
- Agilent Technologies, Inc.
- BD
- Beckman Coulter, Inc.
- Bethyl Laboratories, Inc.
- Bio SB
- BioLegend, Inc.
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- Enzo Life Sciences, Inc.
- F. Hoffmann-La Roche Ltd
- GenScript
- Jackson ImmunoResearch Inc.
- Lonza
- Merck KGaA
- Miltenyi Biotec
- OriGene Technologies, Inc.
- PerkinElmer Inc.
- QIAGEN
- Rockland Immunochemicals, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Read the full report: https://www.reportlinker.com/p06032766/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Research
Antibodies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 2: World 7-Year Perspective for Research Antibodies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2020 & 2027
Table 3: World Current & Future Analysis for Reagent by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 4: World 7-Year Perspective for Reagent by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027
Table 5: World Current & Future Analysis for Antibodies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 6: World 7-Year Perspective for Antibodies by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027
Table 7: World Current & Future Analysis for Pharma & Biotech
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 8: World 7-Year Perspective for Pharma & Biotech
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027
Table 9: World Current & Future Analysis for Academic &
Research Institutions by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 10: World 7-Year Perspective for Academic & Research
Institutions by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2020 & 2027
Table 11: World Current & Future Analysis for Contract Research
Organizations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 12: World 7-Year Perspective for Contract Research
Organizations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2020 & 2027
Table 13: World Current & Future Analysis for Western Blotting
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 14: World 7-Year Perspective for Western Blotting by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 15: World Current & Future Analysis for Flow Cytometry by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 16: World 7-Year Perspective for Flow Cytometry by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 17: World Current & Future Analysis for Enzyme-Linked
Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 18: World 7-Year Perspective for Enzyme-Linked
Immunosorbent Assay (ELISA) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2020 & 2027
Table 19: World Current & Future Analysis for
Immunohistochemistry by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 20: World 7-Year Perspective for Immunohistochemistry by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 21: World Current & Future Analysis for
Immunofluorescence by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 22: World 7-Year Perspective for Immunofluorescence by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 23: World Current & Future Analysis for
Immunoprecipitation by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 24: World 7-Year Perspective for Immunoprecipitation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 25: World Current & Future Analysis for Other
Technologies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 26: World 7-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 27: USA Current & Future Analysis for Research Antibodies
by Product - Reagent and Antibodies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR
Table 28: USA 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 29: USA Current & Future Analysis for Research Antibodies
by End-Use - Pharma & Biotech Companies, Academic & Research
Institutions and Contract Research Organizations - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 30: USA 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 31: USA Current & Future Analysis for Research Antibodies
by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked
Immunosorbent Assay (ELISA), Immunohistochemistry,
Immunofluorescence, Immunoprecipitation and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 32: USA 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
CANADA
Table 33: Canada Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 34: Canada 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 35: Canada Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 36: Canada 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 37: Canada Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 38: Canada 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
JAPAN
Table 39: Japan Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 40: Japan 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 41: Japan Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 42: Japan 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 43: Japan Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 44: Japan 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
CHINA
Table 45: China Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 46: China 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 47: China Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 48: China 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 49: China Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 50: China 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
EUROPE
Table 51: Europe Current & Future Analysis for Research
Antibodies by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR
Table 52: Europe 7-Year Perspective for Research Antibodies by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2020 & 2027
Table 53: Europe Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 54: Europe 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 55: Europe Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 56: Europe 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 57: Europe Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 58: Europe 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
FRANCE
Table 59: France Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 60: France 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 61: France Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 62: France 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 63: France Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 64: France 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
GERMANY
Table 65: Germany Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 66: Germany 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 67: Germany Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 68: Germany 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 69: Germany Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 70: Germany 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
ITALY
Table 71: Italy Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 72: Italy 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 73: Italy Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 74: Italy 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 75: Italy Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 76: Italy 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
UNITED KINGDOM
Table 77: UK Current & Future Analysis for Research Antibodies
by Product - Reagent and Antibodies - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR
Table 78: UK 7-Year Perspective for Research Antibodies by
Product - Percentage Breakdown of Value Sales for Reagent and
Antibodies for the Years 2020 & 2027
Table 79: UK Current & Future Analysis for Research Antibodies
by End-Use - Pharma & Biotech Companies, Academic & Research
Institutions and Contract Research Organizations - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 80: UK 7-Year Perspective for Research Antibodies by
End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Academic & Research Institutions and
Contract Research Organizations for the Years 2020 & 2027
Table 81: UK Current & Future Analysis for Research Antibodies
by Technology - Western Blotting, Flow Cytometry, Enzyme-Linked
Immunosorbent Assay (ELISA), Immunohistochemistry,
Immunofluorescence, Immunoprecipitation and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 82: UK 7-Year Perspective for Research Antibodies by
Technology - Percentage Breakdown of Value Sales for Western
Blotting, Flow Cytometry, Enzyme-Linked Immunosorbent Assay
(ELISA), Immunohistochemistry, Immunofluorescence,
Immunoprecipitation and Other Technologies for the Years 2020 &
2027
REST OF EUROPE
Table 83: Rest of Europe Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 84: Rest of Europe 7-Year Perspective for Research
Antibodies by Product - Percentage Breakdown of Value Sales for
Reagent and Antibodies for the Years 2020 & 2027
Table 85: Rest of Europe Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 86: Rest of Europe 7-Year Perspective for Research
Antibodies by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Academic & Research Institutions
and Contract Research Organizations for the Years 2020 & 2027
Table 87: Rest of Europe Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 88: Rest of Europe 7-Year Perspective for Research
Antibodies by Technology - Percentage Breakdown of Value Sales
for Western Blotting, Flow Cytometry, Enzyme-Linked
Immunosorbent Assay (ELISA), Immunohistochemistry,
Immunofluorescence, Immunoprecipitation and Other Technologies
for the Years 2020 & 2027
ASIA-PACIFIC
Table 89: Asia-Pacific Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 90: Asia-Pacific 7-Year Perspective for Research
Antibodies by Product - Percentage Breakdown of Value Sales for
Reagent and Antibodies for the Years 2020 & 2027
Table 91: Asia-Pacific Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 92: Asia-Pacific 7-Year Perspective for Research
Antibodies by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Academic & Research Institutions
and Contract Research Organizations for the Years 2020 & 2027
Table 93: Asia-Pacific Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 94: Asia-Pacific 7-Year Perspective for Research
Antibodies by Technology - Percentage Breakdown of Value Sales
for Western Blotting, Flow Cytometry, Enzyme-Linked
Immunosorbent Assay (ELISA), Immunohistochemistry,
Immunofluorescence, Immunoprecipitation and Other Technologies
for the Years 2020 & 2027
REST OF WORLD
Table 95: Rest of World Current & Future Analysis for Research
Antibodies by Product - Reagent and Antibodies - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 96: Rest of World 7-Year Perspective for Research
Antibodies by Product - Percentage Breakdown of Value Sales for
Reagent and Antibodies for the Years 2020 & 2027
Table 97: Rest of World Current & Future Analysis for Research
Antibodies by End-Use - Pharma & Biotech Companies, Academic &
Research Institutions and Contract Research Organizations -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 98: Rest of World 7-Year Perspective for Research
Antibodies by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Academic & Research Institutions
and Contract Research Organizations for the Years 2020 & 2027
Table 99: Rest of World Current & Future Analysis for Research
Antibodies by Technology - Western Blotting, Flow Cytometry,
Enzyme-Linked Immunosorbent Assay (ELISA),
Immunohistochemistry, Immunofluorescence, Immunoprecipitation
and Other Technologies - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR
Table 100: Rest of World 7-Year Perspective for Research
Antibodies by Technology - Percentage Breakdown of Value Sales
for Western Blotting, Flow Cytometry, Enzyme-Linked
Immunosorbent Assay (ELISA), Immunohistochemistry,
Immunofluorescence, Immunoprecipitation and Other Technologies
for the Years 2020 & 2027
IV. COMPETITION
Total Companies Profiled: 42
Read the full report: https://www.reportlinker.com/p06032766/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________